Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma
Phase 2
Completed
NCT00942734
| Condition | Head And Neck Cancer |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | M.D. Anderson Cancer Center |
|---|
| Status | Completed |
|---|
| Enrollment | 49 participants |
|---|
| Interventions | Erlotinib, RAD001 |
|---|
| Start date | Jul, 2009 |
|---|
| Completion date | Nov, 2014 |
|---|
| Results posted | Feb 4, 2016 |
|---|
Summary
The goal of this clinical research study is to learn if RAD001 in combination with Tarceva (erlotinib hydrochloride) can help to control head and neck squamous cell cancer (HNSCC). The safety of this drug combination will also be studied.
12-Week Progression-Free Survival (PFS)
12 weeks · Percentage of Participants
| RAD001 + Erlotinib | 48.57 Percentage of Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.